SCHEMBL3378055

SCHEMBL3378055

O=C1C=CN=C2C1=Cc1ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.37
PTPRC P08575 3/20 0.37
IDO1 P14902 2/20 0.37
PTPN1 P18031 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
BCHE P06276 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
ACHE P22303 1/20 0.37
CES1 P23141 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1335811 0.75 S100A4 (0.40) PTPRCKDM4EMEN1ALDH1A1MAPT
SCHEMBL29725127 0.75 S100A4 (0.40) PTPRCKDM4EMEN1ALDH1A1MAPT
SCHEMBL30493712 0.73 ABCG2 (0.38) ABCG2
SCHEMBL1864060 0.73 ABCG2 (0.38) ABCG2
SCHEMBL8342519 0.72 PTPRC (0.41) PTPRCKDM4EMEN1ALDH1A1LMNA
SCHEMBL8987959 0.72 ABCG2 (0.33) ABCG2
Hydrochloric Acid SCHEMBL7340960 0.72 ABCG2 (0.37) ABCG2
SCHEMBL29555333 0.71 ABCG2 (0.37) ABCG2CDC25BCDC25A
SCHEMBL49498 0.67 PTPRC (0.39) PTPRCIDO1PTPN1KDM4EMEN1
SCHEMBL527160 0.67 ABCG2 (0.46) ABCG2PTPRCIDO1PTPN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9012555-A None JP disclosed
JP-9025267-A None JP disclosed
CN-113651755-B 4-azafluorene compound and preparation method and application thereof 山东师范大学 2022-07-29 CN disclosed
CN-113651755-A 4-azafluorene compound and preparation method and application thereof 山东师范大学 2021-11-16 CN disclosed
CN-106831581-B Azaspiro-bifluorene derivative and preparation method thereof 上海大学 2021-07-09 CN disclosed
EP-1844060-B1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2010-11-17 EP disclosed
US-20080161567-A1 Metal Complexes MERCK PATENT GMBH (DE) 2008-07-03 US disclosed
EP-1844060-A1 METAL COMPLEXES Merck Patent GmbH (DE) 2007-10-17 EP disclosed
WO-2006081973-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2006-08-10 WO disclosed
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 US disclosed
US-5300642-A α, α-disubstituted aromatics and heteroaromatics as cognition enhancers THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-04-05 US disclosed
EP-0311010-B1 Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers DU PONT MERCK PHARMA (US) 1994-02-02 EP disclosed
EP-0532054-A1 Process for preparing alpha,alpha-disubstituted aromatics and heteroaromatics as cognition enhancers THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-03-17 EP disclosed
EP-0137333-B1 SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE ALCON LABORATORIES, INC. (US) 1992-12-30 EP disclosed
US-5173489-A α,α-disubstituted aromatics and heteroaromatics as cognition enhancers THE DUPONT MERCK PHARMACEUTICAL CO. (US) 1992-12-22 US disclosed
US-5153211-A Enzyme inhibitors ALCON LABORATORIES, INC. (US) 1992-10-06 US disclosed
US-5070100-A COMPLICATIONS OF DIABETES ALCON LABORATORIES, INC. (US) 1991-12-03 US disclosed
US-4864028-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1989-09-05 US disclosed
US-4537892-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1985-08-27 US disclosed
EP-0137333-A2 Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase ALCON LABORATORIES, INC. (US) 1985-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161567-A1 Metal Complexes SOD1, AP1M1, AP2A1 ABCG2 3444/4885PTPRC 2218/4885IDO1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.